Printer Friendly

OSTEOTECH APPOINTS DR. POSER AS R&D HEAD

 SHREWSBURY, N.J., April 7 /PRNewswire/ -- Osteotech, Inc. (NASDAQ: OSTE) announced today that James W. Poser, Ph.D. will join Osteotech on April 19, 1993 to lead the research team as vice president, research and development. Dr. Poser has 18 years experience in research and development in the field of bone growth augmentation. Most recently Dr. Poser served as technical director for Intermedics Orthopaedics, Inc., concentrating on the development of a matrix to promote growth in skeletal defects. Prior to this, he was associate professor of medicine at the University of Texas Health Science Center in San Antonio focusing on research efforts in bone formation. Patrick McBrayer, president and CEO of Osteotech said that, "with his strong industry and academic background in bone healing, Dr. Poser will enhance the company's continuing effort to provide safe, efficacious and cost effective products and services for application in musculoskeletal surgery."
 In its continuing efforts to ensure that it is utilizing the latest technology advancements in processing human bone tissue for transplantation, Osteotech, Inc., in April 1992 entered into an exclusive, world-wide license with Abtox, Inc., of Mundelein, Ill., for use of its Plazlyte(TM) Sterilization System in the sterilization of bone tissue. "Plazlyte is a low ambient temperature, non-toxic process and therefore has the capability of sterilizing bone tissue without the potential of harming the biological or biomechanical properties of the bone tissue like other traditional final sterilization methods," Mr. McBrayer said. To fully maximize the benefits of this technology, Robert O'Leary, formerly executive vice president, research and development of the company, and a recognized expert in sterilization technology, will devote his full efforts in this area for the company as vice president, tissue sterilization.
 The company also announced today that John C. Callan, senior vice president operations, resigned effective April 2, 1993 to accept a position with Johnson and Johnson in Arlington, Texas. The domestic manufacturing and processing operations of the company will continue to report to Michael J. Jeffries, executive vice president, and a new vice president of operations will be hired to replace Mr. Callan.
 "Osteotech's acquisition of HC Implants BV significantly increased our research opportunities with the addition of ceramic and polymer technology for surgical markets. The research and development capabilities of our combined organizations and the coordination of biologic and biomaterial efforts worldwide will position the company for continued growth through new product and licensing opportunities," stated Mr. McBrayer.
 Osteotech, Inc., headquartered in Shrewsbury, is a leading processor of human bone and bone connective tissue for transplantation and an innovator in the development of biologic and biomaterial products for musculoskeletal surgery.
 -0- 4/7/93
 /CONTACT: Michael J. Jeffries of Osteotech, 908-542-2800/
 (OSTE)


CO: Osteotech, Inc. ST: New Jersey IN: MTC SU: PER

SM-LR -- NY010 -- 3680 04/07/93 09:13 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1993
Words:464
Previous Article:MERRIN DEVELOPS THE FIRST INTERACTIVE TRADING WORKSTATION FOR WALL STREET
Next Article:IMRE CORPORATION ANNOUNCES FIRST QUARTER RESULTS
Topics:


Related Articles
OSTEOTECH PROMOTES ROGER STIKELEATHER TO EXECUTIVE VICE PRESIDENT MARKETING AND SALES
OSTEOTECH ANNOUNCES MANAGEMENT CHANGES
GenSci and DePuy Agree to Extend Relationship.
Stephen Galliker Joins Osteotech Board.
Osteotech Announces Domestic Sales and Marketing Organization Changes.
Osteotech's October 3, 2003 Conference Call Information.
Osteotech Announces Election of New President and Chief Operating Officer.
Osteotech Appoints Two New Board Members.
Osteotech expanding its senior management team.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters